New hope for advanced cancer patients as experimental drug enters human trials
Disease control
Recruiting now
This study tests a new medicine, SNV4818, in about 320 adults with advanced solid tumors that have a specific genetic change (PIK3CA mutation) and have not responded to other treatments. The main goals are to check safety and find the best dose, either alone or with other cancer …
Phase: PHASE1, PHASE2 • Sponsor: Pikavation Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC